Role of Early Versus Late Switch to Lapatinib-Capecitabine
Status:
Terminated
Trial end date:
2010-12-13
Target enrollment:
Participant gender:
Summary
The study will be conducted as a multicenter prospective observational cohort study, trying
to cover almost all Brazilian States, in a population of ErbB2 positive metastatic breast
cancer patients, whose disease has progressed after trastuzumab-containing regimen, comparing
outcomes in two groups: Group 1: patients receiving Lapatinib-capecitabine immediately after
1st Trastuzumab progression (second line treatment), and Group 2: patients receiving
Lapatinib-capecitabine after 2 or more lines of treatment after 1st trastuzumab progression
(third line or greater).